|
Parameters
|
Values
|
|---|
|
Baseline
| |
|
Age (years)
|
48.4±10.2 (29–75)
|
|
BMIa (kg m-2)
|
23.36±3.79 (15.06-38.05)
|
|
Tumor type
| |
|
Infiltrating ductal carcinoma
|
193 (86.55%)
|
|
Ductal carcinoma in situ
|
17 (7.62%)
|
|
Others
|
11 (4.93%)
|
|
Unknown
|
2 (0.90%)
|
|
Side
| |
|
Right
|
100 (44.84%)
|
|
Left
|
114 (51.12%)
|
|
Both
|
9 (4.04%)
|
|
Tumor size
| |
|
<5cm
|
159 (71.30%)
|
|
≥5cm
|
26 (11.66%)
|
|
Unknown
|
38 (17.04%)
|
|
Lymph node involvement
| |
|
Positive
|
121 (53.81%)
|
|
Negative
|
90 (40.36%)
|
|
Unknown
|
12 (5.83%)
|
|
TMN staging
| |
|
Stages 0-2
|
154 (69.06%)
|
|
Stages 3-4
|
30 (13.45%)
|
|
Unknown
|
39 (17.49%)
|
|
ER/PR status
| |
|
Single or double positive
|
144 (64.57%)
|
|
Negative
|
52 (23.32%)
|
|
Unknown
|
27 (12.11%)
|
|
Family history
| |
|
Positive
|
13 (5.83%)
|
|
Negative
|
203 (91.03%)
|
|
Unknown
|
7 (3.14%)
|
|
Post-surgery follow-up
| |
|
Therapies
| |
|
TAM only
|
92 (41.26%)
|
|
TAM and chemotherapy
|
56 (25.11%)
|
|
TAM and radiotherapy
|
10 (4.48%)
|
|
Triple therapy
|
55 (24.66%)
|
|
Unknown
|
10 (4.48%)
|
|
Recurrence
| |
|
With
|
56 (25.11%)
|
|
Without
|
167 (74.89%)
|
|
Mortality
| |
|
With
|
33 (14.80%)
|
|
Without
|
190 (85.20%)
|
|
Progression-free
|
165 (73.99%)
|
|
Mean survival years
| |
|
Recurrence-free
|
9.26±5.31 (0.04-24.52)
|
|
Overall
|
10.14±5.11 (0.14-24.52)
|
- NOTE: Values shown are mean±s.d., or number of patients (% of n).
-
aData from 185 patients. Bold type indicates p<0.050.
- Abbreviations: BMI Body mass index, ER estrogen receptor, PR progesterone receptor, TAM tamoxifen.
